These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 18301801)

  • 1. Etravirine.
    Knoll BM; Vento S; Temesgen Z
    Drugs Today (Barc); 2008 Jan; 44(1):23-33. PubMed ID: 18301801
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Role of etravirine in combination antiretroviral therapy].
    Domingo P
    Enferm Infecc Microbiol Clin; 2009 Dec; 27 Suppl 2():46-51. PubMed ID: 20116628
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Etravirine: the renaissance of non-nucleoside reverse transcriptase inhibitors.
    Jayaweera DT; Espinoza L; Castro J
    Expert Opin Pharmacother; 2008 Dec; 9(17):3083-94. PubMed ID: 19006480
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Etravirine: a second-generation nonnucleoside reverse transcriptase inhibitor (NNRTI) active against NNRTI-resistant strains of HIV.
    Schiller DS; Youssef-Bessler M
    Clin Ther; 2009 Apr; 31(4):692-704. PubMed ID: 19446143
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Etravirine and rilpivirine: nonnucleoside reverse transcriptase inhibitors with activity against human immunodeficiency virus type 1 strains resistant to previous nonnucleoside agents.
    Fulco PP; McNicholl IR
    Pharmacotherapy; 2009 Mar; 29(3):281-94. PubMed ID: 19249947
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Etravirine in the treatment of HIV-1: a clinical overview for healthcare professionals.
    Yeni P; Mills A; Peeters M; Vingerhoets J; Kakuda TN; De Smedt G; Woodfall B
    Curr HIV Res; 2010 Oct; 8(7):564-76. PubMed ID: 20946097
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Etravirine.
    Deeks ED; Keating GM
    Drugs; 2008; 68(16):2357-72. PubMed ID: 18973398
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Next-generation HIV-1 non-nucleoside reverse transcriptase inhibitors.
    Boone LR
    Curr Opin Investig Drugs; 2006 Feb; 7(2):128-35. PubMed ID: 16499282
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Etravirine in first-line therapy].
    Garcés PA; Tena EV
    Enferm Infecc Microbiol Clin; 2009 Dec; 27 Suppl 2():12-20. PubMed ID: 20116623
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Etravirine, a next-generation nonnucleoside reverse-transcriptase inhibitor.
    Johnson LB; Saravolatz LD
    Clin Infect Dis; 2009 Apr; 48(8):1123-8. PubMed ID: 19275497
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-1: 24-week results from a randomised, double-blind, placebo-controlled trial.
    Madruga JV; Cahn P; Grinsztejn B; Haubrich R; Lalezari J; Mills A; Pialoux G; Wilkin T; Peeters M; Vingerhoets J; de Smedt G; Leopold L; Trefiglio R; Woodfall B;
    Lancet; 2007 Jul; 370(9581):29-38. PubMed ID: 17617270
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Etravirine: R165335, TMC 125, TMC-125, TMC125.
    Drugs R D; 2006; 7(6):367-73. PubMed ID: 17073519
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Etravirine: a review of its use in the management of treatment-experienced patients with HIV-1 infection.
    Croxtall JD
    Drugs; 2012 Apr; 72(6):847-69. PubMed ID: 22512366
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Etravirine: new drug. Multidrug-resistant HIV: another option.
    Prescrire Int; 2009 Jun; 18(101):102-3. PubMed ID: 19637414
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Etravirine in highly treatment-experienced patients].
    Palter DP; Corbera EF; Tiraboschi JM
    Enferm Infecc Microbiol Clin; 2009 Dec; 27 Suppl 2():6-11. PubMed ID: 20116622
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of lersivirine versus etravirine for the treatment of HIV-1 infection in patients with prior non-nucleoside reverse transcriptase inhibitor (NNRTI) use and evidence of NNRTI resistance: a randomized phase 2B trial.
    DeJesus E; Fätkenheuer G; Orrell C; Wang C; Jones J; Craig C; Tawadrous M; Heera J
    HIV Clin Trials; 2014; 15(5):209-17. PubMed ID: 25350959
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Introduction. Etravirine: a new standard of potency and safety among non-nucleoside analogues].
    Domingo P
    Enferm Infecc Microbiol Clin; 2009 Dec; 27 Suppl 2():1. PubMed ID: 20116620
    [No Abstract]   [Full Text] [Related]  

  • 18. Efficacy and safety of etravirine in treatment-experienced, HIV-1 patients: pooled 48 week analysis of two randomized, controlled trials.
    Katlama C; Haubrich R; Lalezari J; Lazzarin A; Madruga JV; Molina JM; Schechter M; Peeters M; Picchio G; Vingerhoets J; Woodfall B; De Smedt G;
    AIDS; 2009 Nov; 23(17):2289-300. PubMed ID: 19710593
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Etravirine: A novel nonnucleoside reverse transcriptase inhibitor for managing human immunodeficiency virus infection.
    Elsayed RK; Caldwell DJ
    Am J Health Syst Pharm; 2010 Feb; 67(3):193-205. PubMed ID: 20101061
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prediction of the virological response to etravirine in clinical practice: Comparison of three genotype algorithms.
    Cotte L; Trabaud MA; Tardy JC; Brochier C; Gilibert RP; Miailhes P; Trépo C; André P
    J Med Virol; 2009 Apr; 81(4):672-7. PubMed ID: 19235860
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.